Literature DB >> 7662970

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

S E Antonarakis1, J P Rossiter, M Young, J Horst, P de Moerloose, S S Sommer, R P Ketterling, H H Kazazian, C Négrier, C Vinciguerra, J Gitschier, M Goossens, E Girodon, N Ghanem, F Plassa, J M Lavergne, M Vidaud, J M Costa, Y Laurian, S W Lin, S R Lin, M C Shen, D Lillicrap, S A Taylor, S Windsor, S V Valleix, K Nafa, Y Sultan, M Delpech, C L Vnencak-Jones, J A Phillips, R C Ljung, E Koumbarelis, A Gialeraki, T Mandalaki, P V Jenkins, P W Collins, K J Pasi, A Goodeve, I Peake, F E Preston, M Schwartz, E Scheibel, J Ingerslev, D N Cooper, D S Millar, V V Kakkar, F Giannelli, J A Naylor, E F Tizzano, M Baiget, M Domenech, C Altisent, J Tusell, M Beneyto, J I Lorenzo, C Gaucher, C Mazurier, K Peerlinck, G Matthijs, J J Cassiman, J Vermylen, P G Mori, M Acquila, D Caprino, H Inaba.   

Abstract

Twenty-two molecular diagnostic laboratories from 14 countries participated in a consortium study to estimate the impact of Factor VIII gene inversions in severe hemophilia A. A total of 2,093 patients with severe hemophilia A were studied; of those, 740 (35%) had a type 1 (distal) factor VIII inversion, and 140 (7%) showed a type 2 (proximal) inversion. In 25 cases, the molecular analysis showed additional abnormal or polymorphic patterns. Ninety-eight percent of 532 mothers of patients with inversions were carriers of the abnormal factor VIII gene; when only mothers of nonfamilial cases were studied, 9 de novo inversions in maternal germ cells were observed among 225 cases (approximately 1 de novo maternal origin of the inversion in 25 mothers of sporadic cases). When the maternal grandparental origin was examined, the inversions occurred de novo in male germ cells in 69 cases and female germ cells in 1 case. The presence of factor VIII inversions is not a major predisposing factor for the development of factor VIII inhibitors; however, slightly more patients with severe hemophilia A and factor VIII inversions develop inhibitors (130 of 642 [20%]) than patients with severe hemophilia A without inversions (131 of 821 [16%]).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662970

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Hardy, Weinberg and language impediments.

Authors:  J F Crow
Journal:  Genetics       Date:  1999-07       Impact factor: 4.562

2.  Mutation analysis of factor VIII in Korean patients with severe hemophilia A.

Authors:  Chur-Woo You; Hee-Sook Son; Hee Jin Kim; Eui-Jeon Woo; Soon-Ae Kim; Haing-Woon Baik
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

3.  Antihemophilic factor [recombinant], formulated with sucrose.

Authors: 
Journal:  P T       Date:  2010-09

4.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

5.  Assaying chromosomal inversions by single-molecule haplotyping.

Authors:  Daniel J Turner; Jay Shendure; Greg Porreca; George Church; Peter Green; Chris Tyler-Smith; Matthew E Hurles
Journal:  Nat Methods       Date:  2006-06       Impact factor: 28.547

6.  Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene.

Authors:  M Young; H Inaba; L W Hoyer; M Higuchi; H H Kazazian; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

7.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

10.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.